Worldwide Clinical Trials provides a broad range of clinical research services for studies into the world’s most prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD). Asthma and COPD are particularly relevant as risk factors such as smoking, biomass fuels, pollution, and tuberculosis (TB). COPD is currently the fourth leading cause of death, expected to become the third by 2030. COPD patients are also severely affected by co-morbidities such as heart disease and diabetes. Since 2008, Worldwide has participated in the design, execution, and analysis for over 100 trials involving more than 5,000 patients with respiratory diseases and disorders. Our experts have managed studies with a variety of therapeutic interventions, including numerous trials for steroid inhalation compounds, as well as both short-acting and long-acting bronchodilators on asthma and allergy compounds.